GH4:05 PMGuardant Health to Report Second Quarter 2026 Financial Results on July 30, 2026guardanthealth.com
GH2:50 PMUnitedHealth Group Now Covers Guardant Health’s Shield Blood Test for Colorectal Cancer Screeningguardanthealth.com
GH8:05 AMGuardant Health Announces FDA Approval of Guardant360 CDx as Companion Diagnostic for Boehringer Ingelheim’s HERNEXEOS®guardanthealth.com
GH8:05 AMGuardant Health and Collaborators to Present 38 Abstracts Highlighting Breadth and Expanded Clinical Utility of Guardant Liquid Biopsy Tests Powered by InfinityAI at 2026 ASCO Annual MeetingPresentation / Abstractguardanthealth.com
GH7:47 AMAmerican Cancer Society Recommends Guardant Health’s Shield Blood Test in Updated Colorectal Cancer Screening Guidelinesguardanthealth.com
GH8:05 AMFDA Approves New Guardant360 Liquid CDx, the Largest FDA-Approved Liquid Biopsy Panel with a 100x Expanded Footprintguardanthealth.com
GH4:51 PMGuardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)guardanthealth.com
GH4:05 PMGuardant Health Reports First Quarter 2026 Financial Results and Increases 2026 Revenue Guidanceguardanthealth.com
GH8:05 AMGuardant Health Receives FDA Approval for Guardant360® CDx as a Companion Diagnostic for Arvinas and Pfizer’s VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced Breast Cancer with ESR1 Mutationsguardanthealth.com
GH8:05 AMGuardant Health Announces Multi-Year Strategic Collaboration with Nuvalent to Develop Companion Diagnostics and Support Potential Commercialization of Targeted Cancer Therapies Using the Guardant Infinity™ Platformguardanthealth.com
GH4:05 PMGuardant Health to Report First Quarter 2026 Financial Results on May 7, 2026guardanthealth.com